RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 X-VeRT Results: Rivaroxaban is Safe and Effective for Cardioversion in AF
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 27
SP 27
OP 27
DO 10.1177/155989771427017
UL http://mdc.sagepub.com/content/14/27/27.1.abstract
AB This article presents results from the Explore the Efficacy and Safety of Once-Daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion trial [X-VeRT; Cappato R et al. Eur Heart J. 2014]. The data showed that oral rivaroxaban was as effective and safe as a vitamin K antagonist when administered for only about a week prior to elective cardioversion for atrial fibrillation.